Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$61.89
pos +0.00
+0.00%
Today's Range: 61.87 - 62.63 | MRK Avg Daily Volume: 9,172,500
Last Update: 04/21/17 - 4:00 PM EDT
Volume: 0
YTD Performance: 5.13%
Open: $0.00
Previous Close: $62.55
52 Week Range: $53.06 - $66.80
Oustanding Shares: 2,741,529,731
Market Cap: 171,482,684,674
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 9
Moderate Buy 1 1 1 1
Hold 3 3 3 3
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.68 1.68 1.68 1.68
Latest Dividend: 0.47
Latest Dividend Yield: 3.01%
Dividend Ex-Date: 03/13/17
Price Earnings Ratio: 44.36
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
44.36 44.40 30.40
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.02% 9.35% 8.10%
GROWTH 12 Mo 3 Yr CAGR
Revenue 0.80 -0.10 -0.03
Net Income -11.60 -0.10 -0.04
EPS -9.60 -0.10 -0.02
Earnings for MRK:
EBITDA 11.47B
Revenue 39.81B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $0.83 $0.88 $3.83 $4.19
Number of Analysts 7 6 9 8
High Estimate $0.86 $0.93 $3.88 $4.73
Low Estimate $0.78 $0.82 $3.79 $4.00
Prior Year $0.89 $0.93 $3.78 $3.83
Growth Rate (Year over Year) -6.58% -5.91% 1.23% 9.59%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
- Rev Shark, Yes, Market Lacks Fear, but There's No Emotion Either Several columns from me on the same theme today:   * I Fear the Absence of Fear of Loss  * More Wall Street Nonsense on Display  * Meshuganah Is Trump  * Thinking and Trading Opportunistically on the Short Side   Trade of the Week - Long a current fave - Allergan AGN!
It's pretty normal to have profit-taking after such a strong first quarter.
We know that we are in the era when index managers are ascendant.
Get your plan in place, but understand that the Republic is not in jeopardy.
"I would describe today's market action as "benign." And that applies to almost every asset class." -- Kass Diary

Health Care Putting in a Base Real Money Pro($)

Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (XLV) (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. Last year more than $18 billion was redeemed out of the healthcare ETFs, according to Morningstar. However there are some technical signposts that the two-year period of underperformance might be ending, as a basing seems likely. Look at the chart and note the recent higher high.
Drug companies are the latest targets/beneficiaries.
Bull market number one, perhaps of all time: the financials.
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
You have to keep up with the sector rotations.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.